NewLink Inks $13.5M Deal In Investor Suit Over Cancer Drug

Law360 (February 2, 2021, 6:36 PM EST) -- Investors in biopharmaceutical company NewLink Genetics Corp. told a Manhattan federal judge that they'd reached a $13.5 million deal to settle their proposed securities class action accusing the company and its co-founders of misrepresenting details of a pancreatic cancer drug trial.

In a stipulation and agreement of settlement filed Monday, lead plaintiffs Michael Nguyen and Kelly Nguyen told U.S. District Judge William H. Pauley III that they'd reached the multimillion dollar deal with NewLink, its former CEO Charles J. Link Jr. and its former chief medical officer Nicholas N. Vahanian in December on the heels of an earlier mediation session....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!